Orally active insulin mimics: where do we stand now?
The war against diabetes through the development of new drugs is an ongoing continuous process to counter the alarming global increase in the prevalence of diabetes and its complications, particularly in developing countries like India. Unfortunately, the speed with which our knowledge of diabetes and its effects is expanding is not matched by the availability of new drugs. Following the identification of the insulin receptor (IR), its intrinsic kinase activity and molecular cloning, many studies have looked at IR as an ideal drug target. This review summarizes in brief the latest advancements in this field with particular reference to the current situation in respect of the development of orally active insulin mimetics in the treatment of type 2 diabetes.
KeywordsInsulin mimetic insulin receptor tyrosine kinase PI 3-kinase vanadium
Epidermal growth factor receptor
insulin growth factor-1 receptor
insulin receptor substrate
insulin receptor tyrosine kinase
- PI 3-kinase
platelet-derived growth factor receptor
Unable to display preview. Download preview PDF.
- Balasubramanyam M and Mohan V 1999 The need for high throughput screening of herbal medicine with special reference to diabetes mellitus;Brain storming colloquium on Biodiversity (sponsored by DST), Abstract p 31Google Scholar
- Band C J, Posner B I, Dumas V and Contreres J O 1997 Early signaling events triggered by peroxovanadium [bpV(phen)] are insulin receptor kinase (IRK)-dependent: specificity of inhibition of IRK-associated protein tyrosine phosphatase(s) by bpV(phen);Mol. Endocrinol. 11 1899–1910PubMedCrossRefGoogle Scholar
- Bulangu L N, Ossowski V M, Bogardus C and Mott D 1990 Insulin-sensitive tyrosine kinase: relationship within vivo insulin action in humans;Am. J. Physiol. 258 E964–974Google Scholar
- Elchebly M, Payette P, Michaliszyn E, Cromlish W, Collins S, Loy A L, Normandin D, Cheng A, Himms-Hagen J, Chan C, Ramachandran C, Gresser M J, Tremblay M L and Kennedy B P 1999 Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene;Science 283 1544–1548PubMedCrossRefGoogle Scholar
- Goodyear L J, Giorgino F, Sherman L A, Carey J, Smith R J and Dohm G L 1995 Insulin receptor phosphorylation, insulin receptor substrate-1 phosphorylation, and phosphatidylinositol 3-kinase activity are decreased in intact skeletal muscle strips from obese subjects;J. Clin. Invest. 95 2195–2204PubMedGoogle Scholar
- Gould G W, Merrall N W, Martin S, Jess T J, Campbell I W, Calderhead D M, Gibbs E M, Holman G D and Plevin R J 1994 Growth factor-induced stimulation of hexose transport in 3T3-L1 adipocytes: evidence that insulin-induced translocation of GLUT4 is independent of activation of MAP kinase;Cell Signal. 6 313–320PubMedCrossRefGoogle Scholar
- Haring H U, Obermaier B, Ermel B, Su Z, Mushack J, Rattenhuber E, Holzl J, Kirsch D, Machicao F and Herberg L 1987 Insulin receptor kinase defects as a possible cause of cellular insulin resistance;Diabetes Metab. 13 284–293Google Scholar
- Isakoff S J, Taha C, Rose E, Marcusohn J, Klip A and Skolnik E Y 1995 The inability of phosphatidylinositol 3-kinase activation to stimulate GLUT4 translocation indicates additional signaling pathways are required for insulin-stimulated glucose uptake;Proc. Natl. Acad. Sci. USA 92 10247–10251PubMedCrossRefGoogle Scholar
- Iversen L F, Andersen H S, Branner S, Mortensen S B, Peters G H, Norris K, Olsen O H, Jeppesen C B, Lundt B F, Ripka W, Moller K B and Moller N P 2000 Structure-based design of a low molecular weight, nonphosphorus, nonpeptide, and highly selective inhibitor of protein-tyrosine phosphatase 1B;J. Biol. Chem. 275 10300–10307PubMedCrossRefGoogle Scholar
- Joshi R L, Lamothe B, Gordonnier N, Mesbah K, Monthioux E, Jami J and Bucchini D 1996 Targeted disruption of the insulin receptor gene in the mouse results in neonatal lethality;EMBO J. 15 1542–1547Google Scholar
- Kohn A D, Summers S A, Birnbaum M J and Roth R A 1996 Expression of a constitutively active Akt Ser/Thr kinase in 3T3-L1 adipocytes stimulates glucose uptake and glucose transporter 4 translocation;J. Biol. Chem. 272 31372–31378Google Scholar
- Meyerovitch J, Farfel Z, Sack Y and Shechter Y 1987 Oral administration of vanadate normalizes blood glucose levels in streptozotocin-treated rats;J. Biol. Chem. 263 6658–6662Google Scholar
- Qureshi S A, Ding V, Li Z, Szalkowski D, Biazzo-Ashnault D E, Xie D, Saperstein R, Brady E, Huskey S, Shen X, Liu K, Xu L, Salituro G M, Heck J V, Moller D E, Jones A B and Zhang B B 2000 Activation of insulin signal transduction pathway and anti-diabetic activity of small molecule insulin receptor activators;J. Biol. Chem. 275 36590–36595PubMedCrossRefGoogle Scholar
- Zhang B, Salituro G, Szalkowski D, Li Z, Zhang Y, Royo I, Vilella D, Diez M T, Pelaez F, Ruby C, Kendall R L, Mao X, Griffin P, Calaycay J, Zierath J R, Heck J V, Smith R G and Moller D E 1999 Discovery of a small molecule insulin mimetic with antidiabetic activity in mice;Science 284 974–977PubMedCrossRefGoogle Scholar